meloxicam, rizatriptan · MELOXICAM 20 mg/1; RIZATRIPTAN BENZOATE 10 mg/1 · Tablet · Oral · Axsome Therapeutics, Inc.
NDC 81968-0020-09 · 9 TABLET in 1 BOTTLE · NDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $122.70 per unit over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NP | Jan 30, 2028 |
| patent | 12544383 | Mar 10, 2045 |
| patent | 12005118 | Jan 25, 2043 |
| patent | 12611413 | Dec 29, 2041 |
| patent | 12370196 | Dec 29, 2041 |
| patent | 12551489 | May 28, 2040 |
| patent | 12128052 | May 28, 2040 |
| patent | 12551488 | May 28, 2040 |
| patent | 12472257 | May 18, 2038 |
| patent | 12472256 | May 18, 2038 |
| patent | 12472258 | May 18, 2038 |
| patent | 12616752 | May 18, 2038 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Axsome Therapeutics, Inc. | MELOXICAM 20 mg/1; RIZATRIPTAN BENZOATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Symbravo — NDC 81968-0020-09," retrieved September 3, 2026, https://drugdashboards.com/drug/81968002009.
Free to cite with attribution — see how the data is put together.